REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2024, is made and entered into by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Sponsor”), and the other parties listed on the signature pages hereto and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement (each such party, together with the Sponsor, a “Holder” and collectively, the “Holders”).
DRUGS MADE IN AMERICA ACQUISITION CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks • New York
Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), hereby confirms its agreement with Craft Capital Management LLC (the “Representative”), as representative of the several underwriters named on Schedule A hereto (the “Underwriters” or, each underwriter individually, an “Underwriter”), as follows:
Drugs Made In America Acquisition Corp.Securities Subscription Agreement • August 1st, 2024 • Drugs Made in America Acquisition Corp. • New York
This agreement (the “Agreement”) is entered into on June 14, 2024 by and between Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Subscriber” or “you”), and Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company,” “we” or “us”). Pursuant to the terms hereof, the Company hereby accepts the offer the Subscriber has made to subscribe for and purchase 22,361,111 ordinary shares, $0.0001 par value per share of the Company (the “Shares”), up to 2,916,667 of which are subject to surrender and cancellation by you if the underwriters of the initial public offering (“IPO”) of units (“Units”) of the Company, do not fully exercise their over-allotment option (the “Over-allotment Option”). The Company and the Subscriber’s agreements regarding such Shares are as follows:
INDEMNITY AGREEMENTIndemnification Agreement • September 27th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks • New York
This Agreement, made and entered into effective as of [•], 2024 (“Agreement”), by and between Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (“Company”), and the undersigned indemnitee (“Indemnitee”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This Investment Management Trust Agreement (this “Agreement”) is made effective as of [●], 2024, by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Wilmington Trust, National Association, a national banking association (the “Trustee”), and VStock Transfer LLC, as transfer agent for the Company’s securities (the “Transfer Agent”).
LETTER AGREEMENT Dated [●], 2024Letter Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This letter agreement (this “Letter Agreement”) is entered into by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Sponsor”), and each other undersigned person (each such other undersigned person, an “Insider” and collectively, the “Insiders”). Reference is made to that certain underwriting agreement (the “Underwriting Agreement”) entered into or proposed to be entered into by and between the Company and Clear Street LLC, as representative of the underwriters (the “Representative”), relating to an underwritten initial public offering (the “Public Offering”), of up to 20,000,000 of the Company’s units (including up to 3,000,000 units that may be purchased to cover the underwriters’ option to purchase additional units, if any) (the “Units”), each comprised of one ordinary share of the Company, par value $0.0001 per share (“Ordinary Share”), and one right
DRUGS MADE IN AMERICA ACQUISITION CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • November 25th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks • New York
Drugs Made In America Acquisition Corp., a Cayman Islands exempt company (the “Company”), hereby confirms its agreement with Clear Street LLC (the “Representative”), as representative of the several underwriters named on Schedule A hereto (the “Underwriters” or, each underwriter individually, an “Underwriter”), as follows:
FORM OF PRIVATE UNITS PURCHASE AGREEMENTPrivate Units Purchase Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
RIGHTS AGREEMENTRights Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks • New York
This Rights Agreement (this “Agreement”) is made as of [●], 2024, between Drugs Made In America Acquisition Corp., a Cayman Islands exempted company, with principal offices at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, Florida 33301 (the “Company”) and VStock Transfer, LLC, a New York limited liability company, with offices at 18 Lafayette Place, Woodmere, New York 11598 (the “Rights Agent”).
AMENDMENT TO PROMISSORY NOTEPromissory Note • November 25th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This Amendment (the “Amendment”) to that certain Promissory Note, dated as of June 14, 2024 (the “Note”) by and between Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (“Maker”), and Drugs Made In America Acquisition LLC (“Payee”), is made and entered into effective as of November 21, 2024 by Maker and Payee. All capitalized terms not defined in this Amendment will have the meanings given to them in the Note.
Drugs Made In America Acquisition Corp.Administrative Services Agreement • September 27th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This letter agreement by and between Drugs Made In America Acquisition Corp. (the “Company”) and Drugs Made In America Acquisition LLC (“Sponsor”), will confirm our agreement that, commencing on the effective date (the “Commencement Date”) of the Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “Registration Statement”) for the initial public offering of the Company’s securities and continuing until the earlier of (x) the consummation by the Company of an initial business combination or (y) the Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”):
